Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Brilinta

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

The ‘Million Hour Challenge’

AstraZeneca employees save two million hours through simplification

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

AstraZeneca AZ

AZ speeds first-line lung cancer filing for Tagrisso to EMA

As FLAURA trial results show boosted progression-free survival

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

AstraZeneca AZ

AZ starts pursuit of lung cancer indication for Imfinzi

And its EGFR inhibitor Tagrisso picks up US breakthrough status

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links